Beyond sleepless nights: managing chronic insomnia in adults in primary care

Over the three webinars, our expert speakers will explore the impact of chronic insomnia in diverse patient populations and discuss diagnostic approaches. They will also highlight recommendations for chronic insomnia management in clinical practice, including pharmacological interventions as well as lifestyle and psychological approaches. This is an invaluable opportunity to expand your understanding of chronic insomnia management and have your questions answered in a live Q&A.

Why attend?

Insomnia symptoms are thought to affect 35.0–38.6% of adults and 6.8–14.8% are predicted to have chronic insomnia, yet it remains underdiagnosed and potentially undertreated in primary care.¹

This webinar series aims to:

• Recognise and assess the impact of chronic insomnia on patients’ quality of life
• Provide evidence-based advice on treatment including lifestyle, psychological and pharmacological approaches for managment
• Support patients through long-term management with realistic expectations and sustained engagement

Register for the first webinar in the series now

More webinars in Autumn 2025

Further webinars in the series will be taking place in Autumn 2025 – keep an eye on the website for more details.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.²

References

1. Hafner M, et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023. Accessed June 2025.
2. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, summary of product characteristics

Click here to view prescribing information and adverse event reporting information

This promotional webinar series has been initiated and funded by Idorsia Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.
UK-DA-00903 | June 2025